GlassScriptPhysician profile
Rodrigo Argenal
NPI 1376510206
$6,465.38
in general payments reported to CMS, 2019-2025
12 companies · $36.14 in 2025
The $36.14 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $85.97 · 2020: $27.59 · 2021: $3,561 · 2022: $1,617 · 2023: $1,000 · 2024: $139 · 2025: $36.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,174.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $5,582.75 | 2019-2023 | Dyanavel Xr |
| Glaxosmithkline, LLC. | $168.13 | 2019-2025 | Bexsero, Pediarix, Penmenvy |
| Rhythm Pharmaceuticals, INC. | $141.80 | 2023 | Imcivree |
| Corium, LLC | $123.55 | 2022 | |
| Novo Nordisk INC | $122.42 | 2023 | Sogroya |
| Welch Allyn | $119.08 | 2021 | |
| Ironshore Pharmaceuticals INC. | $117.57 | 2024 | |
| Phadia US INC. | $39.08 | 2022-2025 | Immunocap |
| Verrica Pharmaceuticals INC. | $22.19 | 2023 | Ycanth |
| Sanofi Pasteur INC. | $16.00 | 2023 | |
| Pfizer INC. | $12.81 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rodrigo Argenal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.